Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986517 · 1 trial · 1 indication
For part 1 only
| Arm | Type | Description |
|---|---|---|
| Part 1A Monotherapy Dose Escalation | EXPERIMENTAL | - |
| Part 1B Combination Dose Escalation | EXPERIMENTAL | - |
| Part 1C: Monotherapy PD Sub-study | EXPERIMENTAL | - |
| Part 2A: Monotherapy Dose Expansion Cohort A | EXPERIMENTAL | - |
| Part 2A: Monotherapy Dose Expansion Cohort B | EXPERIMENTAL | - |
| Part 2A: Monotherapy Dose Expansion Cohort C | EXPERIMENTAL | - |
| Part 2B: Combination Dose Expansion Cohort A | EXPERIMENTAL | - |
| Part 2B: Combination Dose Expansion Cohort B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986517 | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have an ECOG performance status of 0 to 1. * Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator). * Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986517 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, with a first-in-human study evaluating its safety and efficacy in participants with advanced solid tumors.
BMS-986517 is being developed by Bristol-Myers Squibb Company (ticker: BMY). The company is conducting a Phase 1/2a first-in-human study of the drug in participants with advanced solid tumors.
BMS-986517 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing study is a Phase 1/2a first-in-human trial in participants with advanced solid tumors.
BMS-986517 is being studied in a Phase 1/2a first-in-human trial (NCT07160725) in participants with advanced solid tumors. The trial is recruiting and aims to enroll 540 participants across the United States, China, Denmark, Japan, and Spain.
Yes, BMS-986517 is a small molecule drug. It is being developed as an oral or injectable therapy for solid tumors, though the specific route of administration is not disclosed in the available clinical trial information.